157 related articles for article (PubMed ID: 33214199)
1. Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast.
Lei T; Pu T; Wei B; Fan Y; Yang L; Shen M; Chen M; Yang J; Zhang Y; Zhang Z; Bu H
J Clin Pathol; 2022 Jan; 75(1):18-23. PubMed ID: 33214199
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma of the breast].
Gao BB; Zheng Q; Yu L; Luo DJ; Nie X; Xu X
Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):843-849. PubMed ID: 36097900
[No Abstract] [Full Text] [Related]
3. Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast.
Honda M; Saji S; Horiguchi S; Suzuki E; Aruga T; Horiguchi K; Kitagawa D; Sekine S; Funata N; Toi M; Kuroi K
Surg Today; 2011 Mar; 41(3):328-32. PubMed ID: 21365411
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
5. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.
Song Y; Liu X; Zhang G; Song H; Ren Y; He X; Wang Y; Zhang J; Zhang Y; Sun S; Liang X; Sun Q; Pang D
World J Surg Oncol; 2013 Jun; 11():129. PubMed ID: 23738706
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
8. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E; Bogina G; Bria E; Vergine M; Zamboni G; Pedron S; Daniele I; Furlanetto J; Carbognin L; Marconi M; Manfrin E; Ibrahim M; Miller K; Tortora G; Molino A; Jasani B; Beccari S; Bonetti F; Chilosi M; Martignoni G; Brunelli M
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1563-8. PubMed ID: 23892410
[TBL] [Abstract][Full Text] [Related]
9. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
10. Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity.
Lim KH; Oh DY; Chie EK; Han W; Im SA; Kim TY; Park IA; Noh DY; Ha SW; Bang YJ
Jpn J Clin Oncol; 2010 Feb; 40(2):112-8. PubMed ID: 19887523
[TBL] [Abstract][Full Text] [Related]
11. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
12. The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines.
Yang L; Chen M; Pu T; Wu S; Wei B; Yang J; Bu H; Zhang Z
J Clin Pathol; 2020 May; 73(5):283-290. PubMed ID: 31732618
[TBL] [Abstract][Full Text] [Related]
13. HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.
Guo W; Wang W; Zhu Y; Zhu X; Shi Z; Wang Y
Int J Clin Exp Pathol; 2015; 8(7):8008-17. PubMed ID: 26339367
[TBL] [Abstract][Full Text] [Related]
14. The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status.
Gamrani S; Akhouayri L; Boukansa S; Karkouri M; El Fatemi H
Breast J; 2023; 2023():6621409. PubMed ID: 38075551
[TBL] [Abstract][Full Text] [Related]
15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
16. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
[TBL] [Abstract][Full Text] [Related]
17. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
Samiei S; van Kaathoven BN; Boersma L; Granzier RWY; Siesling S; Engelen SME; de Munck L; van Kuijk SMJ; van der Hulst RRJW; Lobbes MBI; Smidt ML; van Nijnatten TJA
Ann Surg Oncol; 2019 Nov; 26(12):3902-3909. PubMed ID: 31359276
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
19. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic features and prognosis of triple negative breast cancer].
Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
